Biomarkers, Cardiac Function and Preserved Ejection Fraction

Increased Plasma Pyruvate Kinase M2 (PK‐M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications

Journal of the American Heart Association

JANUARY 16, 2025

U/mL,P<0.001), and these levels correlated with HF severity (New York Heart Association cardiac function class). Patients with reduced left ventricular ejection fraction had higher PKM2 concentrations than those with preserved ejection fraction (18.34.5 versus 7.82.3 versus 16.73.6

Cardiac Function

Cardiac Function Heart Failure Biomarkers Preserved Ejection Fraction

Echocardiographic assessment of the relationship between cardiac function and plasma homocysteine levels in patients with heart failure and preserved ejection fraction

Frontiers in Cardiovascular Medicine

MARCH 9, 2025

BackgroundHeart failure with preserved ejection fraction (HFpEF) is characterized by normal ejection fraction and diastolic dysfunction. ConclusionsThe findings indicate that elevated plasma homocysteine is associated with myocardial remodeling and impaired diastolic function in HFpEF patients.

Preserved Ejection Fraction

Preserved Ejection Fraction Cardiac Function Heart Failure Bicuspid/Mitral

Cardiovascular Update

Increased Plasma Pyruvate Kinase M2 (PK‐M2) in Heart Failure: A Novel Biomarker Related to Cardiac Function and its Clinical Implications

Echocardiographic assessment of the relationship between cardiac function and plasma homocysteine levels in patients with heart failure and preserved ejection fraction

Stay Connected